Claims for Patent: 10,981,919

Summary for Patent: 10,981,919

Title:	Selective PI3K delta inhibitors
Abstract:	The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
Inventor(s):	Vakkalanka; Swaroop K. (La Chaux-de-Fonds, CH), Muthuppalaniappan; Meyyappan (Hyderabad, IN), Nagarathnam; Dhanapalan (Bethany, CT)
Assignee:	Rhizen Pharmaceuticals SA (Basel, CH)
Application Number:	16/776,327
Patent Claims:	1. (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]-p- yrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one. 2. A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable carrier. 3. The pharmaceutical composition of claim 2, wherein the compound has an enantiomeric excess of at least 98%. 4. A method treating indolent non-Hodgkin's lymphoma in a human subject in need thereof comprising administering to the human subject an effective amount of (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)- 1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 5. The method of claim 4, wherein an effective amount of (S)-2-(1-(4-amino -3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate is administered. 6. The method of claim 5, wherein the (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H -chromen-4-one 4-methylbenzenesulfonate has an enantiomeric excess of at least 95%. 7. The method of claim 5, wherein the (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H -chromen-4-one 4-methylbenzenesulfonate has an enantiomeric excess of at least 98%. 8. The method of claim 4, further comprising the step of administering simultaneously or sequentially to the subject at least one other anti-cancer agent. 9. A method of treating follicular lymphoma in a human subject in need thereof comprising administering to the human subject an effective amount of (S)-2-(1-(4-amino-3-(3-fluoro -4-isopropoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H -chromen-4-one or a pharmaceutically acceptable salt thereof. 10. The method of claim 9, wherein an effective amount of (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate is administered. 11. The method of claim 10, wherein the (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one 4-methylbenzenesulfonate has an enantiomeric excess of at least 95%. 12. The method of claim 10, wherein the (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrim- idin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H -chromen-4-one 4-methylbenzenesulfonate has an enantiomeric excess of at least 98%. 13. The method of claim 9, further comprising the step of administering simultaneously or sequentially to the subject at least one other anti-cancer agent.